Lerodalcibep can be a treatment option for patients requiring additional LDL-C reduction: GlobalData
Lerodalcibep is a novel therapy designed to lower low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Biologics License Application
US FDA accepts Amneal’s Biologics License Application for Bevacizumab
Bevacizumab represents the third biosimilar BLA currently filed by Amneal with the FDA
US FDA accepts biologics license application from Lupin for pegfilgrastim biosimilar
This BLA expands the company's oncology portfolio
USFDA defers action on BLA for Avastin biosimilar, notifies Biocon Biologics, Mylan
To complete the application, the agency noted that an inspection of the manufacturing facility is required as a part of the…
US FDA accepts Mylan and Biocon’s proposed biosimilar bevacizumab for review
The FDA goal date set under the Biosimilar User Fee Act (BsUFA) is December 27, 2020
Biocon and Mylan announced that the US…